Small Molecules that Correct RNA Splicing

At Skyhawk Therapeutics we use proprietary structural, kinetic, and computational models to invent small molecules that correct splicing in RNA, targeting some of the world's most intractable diseases

PARTNERS

IN THE NEWS

Bill Haney adds cancer R&D powerhouse Merck to Skyhawk's

roster of partners out to drug RNA

This morning Skyhawk is announcing that pharma giant Merck has stepped up with its own initiative on neurodegeneration while adding cancer to the RNA menu of collaborative specialties at the upstart drug discovery unit for the first time...

IN THE NEWS

Celgene execs shell out $92M cash for a pair of R&D deals that

will fit perfectly in their new home at Bristol-Myers

Celgene is shelling out $80 million in a cash upfront to add oncology, immuno-oncology and autoimmune diseases to the initial roundup of neurological targets mapped early in Skyhawk’s existence.

BIOCENTURY

Skyhawk’s $80M Celgene deal expands remit to autoimmune

In Skyhawk’s fifth deal of the year, the company is moving into a new therapeutic area and adding $80 million to its cash reserve. Skyhawk partnered with Celgene to discover and develop small molecules for autoimmune disease and cancer against hard-to-drug targets that have been clinically validated, or genetically associated with a disease.

C&EN

C&EN’s 2019 10 Start-Ups to Watch

Skyhawk Therapeutics: Drugging RNA splicing with small molecules to treat disease

WHAT WE DO

Our proprietary small molecule platform targets accelerates the discovery and development of drugs that correct RNA mis-splicing across a broad range of disease types:

ONCOLOGY

NEUROLOGY

INFLAMMATORY

INFECTIOUS

RARE

NEUROMUSCULAR

& METABOLIC

LEARN MORE